THIS ANNOUNCEMENT WAS DEEMED BY THE COMPANY TO CONTAIN INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. WITH THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN

9 December 2025 

VENTURE LIFE GROUP PLC

("Venture Life" or the "Company")

Sale of non-core products for up to £4.5m in cash on a cash free, debt free basis

Venture Life (AIM: VLG), a leader in product innovation, development and commercialisation within the global consumer healthcare sector, announces that, further to the disclosure made in the FY24 Final Results announcement, it has completed the sale of its Ultradex and Dentyl brands, including 100 per cent. of the issued share capital of Periproducts Limited, (the "Oral Care Assets") for an enterprise value of up to £4.5 million (the "Sale") on a cash free, debt free basis to Covestus Holdings Ltd.

The consideration for the Sale is payable in cash, with £3.75m paid to the Company on completion that is subject to customary working capital adjustments. A further amount of up to £0.75m will be payable in cash contingent upon the Oral Care Assets achieving expected trading results for the 12 months post completion. As part of the Sale, the Oral Care Assets and the Company will enter into a transitional services agreement until end of February 2026 to ensure a smooth transition.

The net proceeds of the Sale will further bolster Venture Life and its subsidiaries (the "Group") with additional financial resources for its acquisition strategy.

Strategic rationale

The Oral Care Assets do not form part of the future strategic direction of the Company and so the decision has been taken to divest of these assets. Venture Life is now focusing its efforts and resources on the Group's higher margin, higher growth core brands in its key target categories, to promote and support the Proactive Healthy Longevity of consumers. Its current core brands include Balance Activ, Health & Her/Him, Lift and Earol,  (collectively the "Power Brands"), and the funds raised through the Sale will be utilised alongside the existing available funds of the business to drive innovation and growth in the Power Brands, as well as to acquire interesting complementary brands with a pathway to profitable growth.

The Sale also presents the opportunity for the Board to further streamline the Company's operations and product portfolio through the disposal of non-core assets and to focus additional resources into the commercialisation, growth and development of the Power Brands. At the same time, it enables the Company to realise cash at a multiple of c.11x FY24 adjusted EBITDA, which it can redeploy both into the organic growth of its existing Power Brands and the acquisition of carefully selected, margin accretive, high growth assets within the Group's core categories of interest.

For the financial year ended 31 December 2024 the audited results of the Oral Care Assets generated revenues of £4.3 million and adjusted EBITDA of £0.4 million. As at 30 November 2025, the Oral Care Assets had a net carrying value of £4.5 million.

Jerry Randall, Chief Executive Officer, commented: "I am pleased that we have been able to divest of these non-core assets to a new owner that will continue to develop them. As we have indicated before these assets no longer form part of our strategic vision for Venture Life, so the divestment allows us to recycle the funds raised into our core focus categories and brands working out our 5-pillar strategic growth plan.

I am delighted with the post divestment progress since we disposed of our CDMO businesses earlier this year, and the collaboration with the Healthea Group (the purchasers of our CDMO businesses) where we are growing and strengthening the ongoing relationship for our mutual profitable growth. Aswell as generating significant funds for us to drive the growth of Venture Life, the divestment to the Healthea Group has also bought significant operational benefits including accelerated innovation opportunities and strengthened quality of supply. These two divestments have significantly simplified the Group and in conjunction with our new Microsoft D365 ERP system, which is now going live, we have a much more streamlined, agile and scalable business."

For further information, please contact:

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, the Health and Her product range supporting the hormonal lifecycle, the UltraDEX and Dentyl oral care product ranges. The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples and are sold in over 90 countries worldwide. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.